Mesnex Related Published Studies
Well-designed clinical trials related to Mesnex (Mesna)
MESNA (sodium 2-mercaptoethanesulfonate) for prevention of contrast medium-induced nephrotoxicity - controlled trial. [2011.04]
Mesna for the treatment of hyperhomocysteinemia in hemodialysis patients. [2009]
Mesna for treatment of hyperhomocysteinemia in hemodialysis patients: a placebo-controlled, double-blind, randomized trial. [2008.07]
Mesna for Treatment of Hyperhomocysteinemia in Hemodialysis Patients: A Placebo-Controlled, Double-Blind, Randomized Trial. [2008.03.12]
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. [2007.11]
Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide. [2003.12.01]
Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects. [1998.10]
Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy. [1998.09]
Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamide. [1998.02]
Oral ifosfamide/mesna versus intravenous ifosfamide/mesna in non-small-cell lung cancer: a randomized phase II trial of the EORTC lung cancer cooperative group. [1996.08]
Phase II evaluation of ifosfamide/mesna in metastatic prostate cancer. A Southwest Oncology Group study. [1996.08]
A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study. [1996.06]
The effect of short-term instillation of a mucolytic agent (mesna) on airway resistance in mechanically ventilated patients. [1995.04]
A prospective randomized evaluation of three schedules of mesna administration in patients receiving an ifosfamide-containing chemotherapy regimen: sustained efficiency and simplified administration. [1995]
Mesna compared with continuous bladder irrigation as uroprotection during high-dose chemotherapy and transplantation: a randomized trial. [1993.07]
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. [1993.07]
Feasibility and efficacy of arginine 2-mercaptoethanesulfonate (ARGIMESNA) in the prevention of hemorragic cystitis from ifosfamide (IFO). [1992.04]
Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation. [1991.11]
Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders. [1991]
Well-designed clinical trials possibly related to Mesnex (Mesna)
High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial. [2011.06.07]
Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Cooperative Oncology Group (HeCOG) study. [2009.08]
Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303). [2008.10]
The effectiveness of combined treatment with methylprednisolone and cyclophosphamide in oral paraquat poisoning. [2008.07]
Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. [2007.02.10]
Long-term results of dose density therapy in patients with aggressive lymphoma. [2005.04]
Report of an early stopped randomized trial comparing cisplatin vs. cisplatin/ifosfamide/ 5-fluorouracil in recurrent cervical cancer. [2005]
Chemically assisted dissection of tissues in laparoscopic excision of endometriotic cysts. [2003.05]
Influence of mucolytic therapy on respiratory mechanics in patients with chronic obstructive pulmonary disease. [2002.03.28]
Anticipated administration of GM-CSF in the treatment of non small cell lung cancer. [2001.09]
Superiority of high-dose platinum (cisplatin and carboplatin) compared to carboplatin alone in combination chemotherapy for small-cell lung carcinoma: a prospective randomised trial of 280 consecutive patients. [2001.05]
Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. [2001.03.01]
Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: a randomized phase II trial in small-cell lung cancer patients. [2001.02.01]
Chemically assisted dissection of tissues: an interesting support in abdominal myomectomy. [2000.07]
Stem cell factor leads to reduced blood processing during apheresis or the use of whole blood aliquots to support dose-intensive chemotherapy. [1998.07]
Randomized trial showing equivalent efficacy of filgrastim 5 micrograms/kg/d and 10 micrograms/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas. [1997.05]
Increased numbers of long-term culture-initiating cells in the apheresis product of patients randomized to receive increasing doses of stem cell factor administered in combination with chemotherapy and a standard dose of granulocyte colony-stimulating factor. [1996.11.01]
Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial. [1996.08]
High-dose folinic acid and fluorouracil with or without ifosfamide is an inactive combination in advanced pancreatic cancer. A randomized phase II study of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). [1996.06]
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. [1995.12.07]
Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. [1995.10]
Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer. [1995.07]
Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation. [1995.05]
An ongoing randomized study of neoadjuvant chemotherapy in resectable non-small cell lung cancer. [1994.06]
Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination. [1994]
Mitomycin, ifosfamide, and cisplatin in non-small cell lung cancer. [1993.04]
Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: a phase II study of the EORTC Lung Cancer Cooperative Group. [1993]
Dana-Farber Cancer Institute studies in advanced sarcoma. [1990.02]
[Risk-adapted therapy of highly malignant non-Hodgkin's lymphomas with COP-BLAM/IMVP-16: a prospective multicenter study] [1989.02]
[Clinical experiences with polyethylene glycol-bound E. coli L-asparaginase in patients with multiple recurrences of acute lymphoblastic leukemia] [1988.05]
[Multicenter prospective risk-adapted study on the therapy of non-Hodgkin's lymphomas of high malignancy. Use of COP-BLAM/IMVP-16 and randomized adjuvant radiotherapy--study concept and preliminary results] [1988.02]
Other research related to Mesnex (Mesna)
Endoscopic submucosal dissection with a flexible Maryland dissector: randomized comparison of mesna and saline solution for submucosal injection (with videos). [2011.10]
Severe allergic reactions to thiol-based cytoprotective agents mesna and amifostine in a child with a supratentorial primitive neuroectodermal tumor. [2011.08]
Two consecutive cases of platinum-refractory pulmonary pleomorphic carcinoma that showed dramatic responses to MAID (mesna, doxorubicin, ifosfamide and dacarbazine) chemotherapy. [2011.03]
Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP. [2010.09]
MESNA for chemically assisted tissue dissection. [2010.06]
Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients. [2010.02]
Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP. [2009.09.29]
Mesna protects splanchnic organs from oxidative stress induced by pneumoperitoneum. [2009.03]
Protection against cisplatin-induced ovarian damage by the antioxidant sodium 2-mercaptoethanesulfonate (mesna) in female rats. [2008.04]
Chemically assisted endoscopic mechanical submucosal dissection by using mesna. [2008.03]
Prophylaxis with mesna prevents oxidative stress induced by ischemia reperfusion in the intestine via inhibition of nuclear factor-kappaB activation. [2008.02]
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. [2007.09.04]
Adverse hypersensitivity reactions to mesna as adjunctive therapy for cyclophosphamide. [2007.09]
Mesna as a nonvitamin intervention to lower plasma total homocysteine concentration: implications for assessment of the homocysteine theory of atherosclerosis. [2007.08]
A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary. [2007.05]
Histological changes in bladders of patients submitted to ifosfamide chemotherapy even with mesna prophylaxis. [2007.04]
The effect of mesna on plasma total homocysteine concentration in hemodialysis patients. [2007.01]
Mesna protects intestinal mucosa from ischemia/reperfusion injury. [2006.08]
Ifosfamide/mesna as salvage therapy in platinum pretreated ovarian cancer patients--long-term results of a phase II study. [2006.02]
Comparison of uroprotective efficacy of mesna and amifostine in Cyclophosphamide- induced hemorrhagic cystitis in rats. [2006.01]
In vivo generation of angiostatin isoforms by administration of a plasminogen activator and a free sulfhydryl donor: a phase I study of an angiostatic cocktail of tissue plasminogen activator and mesna. [2005.09.01]
Contribution of flavonoid antioxidants to the preventive effect of mesna in cyclophosphamide-induced cystitis in rats. [2005.08]
A phase I study of prolonged ambulatory infusion of Ifosfamide with oral mesna. [2005.05]
Attenuation of bleomycin-induced lung fibrosis in rats by mesna. [2005.02.10]
Protective effects of MESNA (2-mercaptoethane sulphonate) against acetaminophen-induced hepatorenal oxidative damage in mice. [2005.01]
Doxorubicin and ifosfamide-mesna in advanced and recurrent uterine sarcomas. [2005]
Protective effect of MESNA (2-mercaptoethane sulfonate) against hepatic ischemia/reperfusion injury in rats. [2005]
Contribution of antioxidants to preventive effect of mesna in cyclophosphamide-induced hemorrhagic cystitis in rats. [2004.11]
Mesna (2-mercaptoethane sulfonate) prevents ischemia/reperfusion induced renal oxidative damage in rats. [2004.09.24]
Mesna ameliorates intestinal mucosa damage after ifosfamide administration in the rabbit at a dose-related manner. [2004.09]
2-Mercaptoethane sulfonate (MESNA) protects against burn-induced renal injury in rats. [2004.09]
Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children. [2004.09]
Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats. [2004.04.19]
Ifosfamide, mesna, and interferon-alpha2A combination chemoimmunotherapy in malignant mesothelioma: results of a single center in central anatolia. [2004]
Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients. [2004]
Pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion. [2003.12]
Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis. [2003.11]
The effectiveness of sodium 2-mercaptoethane sulfonate (mesna) in reducing capsular formation around implants in a rabbit model. [2003.10]
A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed mullerian tumors with evaluation of potential molecular targets. [2003.09]
High-dose ifosfamide with mesna and granuloctye-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma. [2003.07.15]
Effect of the antioxidant Mesna (2-mercaptoethane sulfonate) on experimental colitis. [2003.06]
Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: a case report. [2003.06]
Lack of effects of sodium 2-mercaptoethane sulfonate (mesna) on Ochratoxin A induced renal tumorigenicity following life-time oral administration of Ochratoxin A in DA and Lewis rats. [2003.04.30]
Mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy for gynecological sarcomas. [2002.11]
U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid. [2002]
Blood thiols following amifostine and mesna infusions, a pediatric oncology group study. [2001.11]
Effect of mesna on lethal effect and hematological toxicity of taxol and vepeside in mice. [2001.09]
Prevention of further cyclophosphamide induced hemorrhagic cystitis by hyperbaric oxygen and mesna in guinea pigs. [2001.09]
Mesna: a novel renoprotective antioxidant in ischaemic acute renal failure. [2001.03]
Variation in administration of cyclophosphamide and mesna in the treatment of childhood malignancies. [2001.01]
Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione. [2000.04]
|
